Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tipifarnib Window Therapy in JMML
NCT00025038Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2001
- Primary completion
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tipifarnib in juvenile myelomonocytic leukemia (JMML), sponsored by National Cancer Institute. Primary endpoints: Response rate (CR or PR) up to 6 years, Safety and toxicity of this regimen up to 6 years and 3 more. Started Jun 2001; status: completed.
02
Drugs
tipifarnib
03
Conditions
juvenile myelomonocytic leukemia (JMML)
Beyond the preview
Go deeper on NCT00025038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00025038.